Pilot Study: Assessment of the Treatment of Osteoporosis in Al-Jouf

Authors

  • Nehad J. AHMED , Ayman K. SALAH , Eman M. ALJAWHARI

Abstract

This study aimed to assess the treatment of osteoporosis in Al-Jouf. The patients who didn’t
have osteoporosis or osteopenia were excluded from the study. Most of the patients were females (78.12%)
and the age of the majority of them was more than 49 (93.75%). About 12.5 % of the patients in the present
study had osteopenia (T-score between -1 and -2.5) and 87.5% of them had osteoporosis (T-score of -2.5 or
lower). Most of the patients used denosumab (81.25%). More than 37% of the patients had hypertension,
25% of them suffered from diabetes. Although the first line drug to treat osteoporosis is the use of one of the
bisphosphonates, most of the patients in the current study used denosumab. Fortunately, both denosumab
and alendronate improved the bone density of the patients. More assessment of the osteoporotic patient is
required in order to reduce the risk of fractures.

Published

2022-11-15

Issue

Section

Articles